125 related articles for article (PubMed ID: 11559212)
1. Vascular involvement in the prognosis of primary cutaneous melanoma.
Kashani-Sabet M; Sagebiel RW; Ferreira CM; Nosrati M; Miller JR
Arch Dermatol; 2001 Sep; 137(9):1169-73. PubMed ID: 11559212
[TBL] [Abstract][Full Text] [Related]
2. NF-kappa B in the vascular progression of melanoma.
Kashani-Sabet M; Shaikh L; Miller JR; Nosrati M; Ferreira CM; Debs RJ; Sagebiel RW
J Clin Oncol; 2004 Feb; 22(4):617-23. PubMed ID: 14966085
[TBL] [Abstract][Full Text] [Related]
3. Independent prognostic importance of vascular invasion in nodular melanomas.
Straume O; Akslen LA
Cancer; 1996 Sep; 78(6):1211-9. PubMed ID: 8826942
[TBL] [Abstract][Full Text] [Related]
4. Lymphatic invasion identified by monoclonal antibody D2-40, younger age, and ulceration: predictors of sentinel lymph node involvement in primary cutaneous melanoma.
Niakosari F; Kahn HJ; McCready D; Ghazarian D; Rotstein LE; Marks A; Kiss A; From L
Arch Dermatol; 2008 Apr; 144(4):462-7. PubMed ID: 18427039
[TBL] [Abstract][Full Text] [Related]
5. Prognostic factors in patients with thick cutaneous melanoma (> 4 mm).
Zettersten E; Sagebiel RW; Miller JR; Tallapureddy S; Leong SP; Kashani-Sabet M
Cancer; 2002 Feb; 94(4):1049-56. PubMed ID: 11920475
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors in localized invasive cutaneous melanoma: high value of mitotic rate, vascular invasion and microscopic satellitosis.
Nagore E; Oliver V; Botella-Estrada R; Moreno-Picot S; Insa A; Fortea JM
Melanoma Res; 2005 Jun; 15(3):169-77. PubMed ID: 15917698
[TBL] [Abstract][Full Text] [Related]
7. Tumor vascularity in the prognostic assessment of primary cutaneous melanoma.
Kashani-Sabet M; Sagebiel RW; Ferreira CM; Nosrati M; Miller JR
J Clin Oncol; 2002 Apr; 20(7):1826-31. PubMed ID: 11919240
[TBL] [Abstract][Full Text] [Related]
8. Detection of lymphatic invasion in primary melanoma with monoclonal antibody D2-40: a new selective immunohistochemical marker of lymphatic endothelium.
Niakosari F; Kahn HJ; Marks A; From L
Arch Dermatol; 2005 Apr; 141(4):440-4. PubMed ID: 15837861
[TBL] [Abstract][Full Text] [Related]
9. Clinical and histopathologic predictors of survival in patients with malignant melanoma: a population-based study in Sweden.
Thörn M; Pontén F; Bergström R; Sparén P; Adami HO
J Natl Cancer Inst; 1994 May; 86(10):761-9. PubMed ID: 8169974
[TBL] [Abstract][Full Text] [Related]
10. Histological lymphovascular invasion is associated with nodal involvement, recurrence, and survival in patients with cutaneous malignant melanoma.
Tas F; Erturk K
Int J Dermatol; 2017 Feb; 56(2):166-170. PubMed ID: 27778319
[TBL] [Abstract][Full Text] [Related]
11. The vascularity of primary cutaneous melanoma.
Fallowfield ME; Cook MG
J Pathol; 1991 Jul; 164(3):241-4. PubMed ID: 1890549
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Significance of Periadnexal Extension in Cutaneous Melanoma and its Implications for Pathologic Reporting and Staging.
Dodds TJ; Lo S; Jackett L; Nieweg O; Thompson JF; Scolyer RA
Am J Surg Pathol; 2018 Mar; 42(3):359-366. PubMed ID: 29240580
[TBL] [Abstract][Full Text] [Related]
13. Defining the role of CD2 in disease progression and overall survival among patients with completely resected stage-II to -III cutaneous melanoma.
Harcharik S; Bernardo S; Moskalenko M; Pan M; Sivendran M; Bell H; Hall LD; Castillo-Martín M; Fox K; Cordon-Cardo C; Chang R; Sivendran S; Phelps RG; Saenger Y
J Am Acad Dermatol; 2014 Jun; 70(6):1036-44. PubMed ID: 24698703
[TBL] [Abstract][Full Text] [Related]
14. Highly sensitive multivariable assay detection of melanocytic differentiation antigens and angiogenesis biomarkers in sentinel lymph nodes with melanoma micrometastases.
Vitoux D; Mourah S; Kerob D; Verola O; Basset-Seguin N; Baccard M; Schartz N; Ollivaud L; Archimbaud A; Servant JM; Revol M; Toubert ME; Podgorniak MP; Plassa F; Porcher R; Lebbé C
Arch Dermatol; 2009 Oct; 145(10):1105-13. PubMed ID: 19841396
[TBL] [Abstract][Full Text] [Related]
15. Novel role for RGS1 in melanoma progression.
Rangel J; Nosrati M; Leong SP; Haqq C; Miller JR; Sagebiel RW; Kashani-Sabet M
Am J Surg Pathol; 2008 Aug; 32(8):1207-12. PubMed ID: 18580492
[TBL] [Abstract][Full Text] [Related]
16. The role of microsatellites as a prognostic factor in primary malignant melanoma.
Shaikh L; Sagebiel RW; Ferreira CM; Nosrati M; Miller JR; Kashani-Sabet M
Arch Dermatol; 2005 Jun; 141(6):739-42. PubMed ID: 15967920
[TBL] [Abstract][Full Text] [Related]
17. Primary cutaneous melanoma. Optimized cutoff points of tumor thickness and importance of Clark's level for prognostic classification.
Büttner P; Garbe C; Bertz J; Burg G; d'Hoedt B; Drepper H; Guggenmoos-Holzmann I; Lechner W; Lippold A; Orfanos CE
Cancer; 1995 May; 75(10):2499-2506. PubMed ID: 7736394
[TBL] [Abstract][Full Text] [Related]
18. Thick cutaneous malignant melanoma: a reappraisal of prognostic factors.
Massi D; Borgognoni L; Franchi A; Martini L; Reali UM; Santucci M
Melanoma Res; 2000 Apr; 10(2):153-64. PubMed ID: 10803716
[TBL] [Abstract][Full Text] [Related]
19. The sentinel lymph node status is an important factor for predicting clinical outcome in patients with Stage I or II cutaneous melanoma.
Statius Muller MG; van Leeuwen PA; de Lange-De Klerk ES; van Diest PJ; Pijpers R; Ferwerda CC; Vuylsteke RJ; Meijer S
Cancer; 2001 Jun; 91(12):2401-8. PubMed ID: 11413531
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors in melanoma patients with tumor-negative sentinel lymph nodes.
Egger ME; Bhutiani N; Farmer RW; Stromberg AJ; Martin RC; Quillo AR; McMasters KM; Scoggins CR
Surgery; 2016 May; 159(5):1412-21. PubMed ID: 26775577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
